In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed the day trading at $105.93 down -6.42% from the previous closing price of $113.2. In other words, the price has decreased by -$6.42 from its previous closing price. On the day, 2.57 million shares were traded. JAZZ stock price reached its highest trading level at $113.04 during the session, while it also had its lowest trading level at $105.02.
Ratios:
For a better understanding of JAZZ, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.07. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 1.47 whereas as Long-Term Debt/Eq ratio is at 1.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on July 15, 2025, initiated with a Buy rating and assigned the stock a target price of $152.
On March 07, 2025, UBS Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $145 to $179.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when COZADD BRUCE C sold 1,000 shares for $113.21 per share. The transaction valued at 113,210 led to the insider holds 435,973 shares of the business.
COZADD BRUCE C bought 9,000 shares of JAZZ for $1,096,210 on Aug 01 ’25. On Jul 01 ’25, another insider, COZADD BRUCE C, who serves as the Chairman & CEO of the company, sold 1,000 shares for $107.63 each. As a result, the insider received 107,630 and left with 436,973 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 6425586688 and an Enterprise Value of 10231601152. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.57 while its Price-to-Book (P/B) ratio in mrq is 1.73. Its current Enterprise Value per Revenue stands at 2.504 whereas that against EBITDA is 7.232.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.24, which has changed by -0.06231743 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $148.06, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is -4.66%, while the 200-Day Moving Average is calculated to be -10.72%.
Shares Statistics:
Over the past 3-months, JAZZ traded about 859.76K shares per day on average, while over the past 10 days, JAZZ traded about 800390 shares per day. A total of 60.64M shares are outstanding, with a floating share count of 57.78M. Insiders hold about 4.51% of the company’s shares, while institutions hold 99.27% stake in the company. Shares short for JAZZ as of 1752537600 were 5726751 with a Short Ratio of 6.66, compared to 1749772800 on 5828993. Therefore, it implies a Short% of Shares Outstanding of 5726751 and a Short% of Float of 10.94.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Jazz Pharmaceuticals plc (JAZZ) is currently attracting attention from 17.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $5.72, with high estimates of $6.17 and low estimates of $5.17.
Analysts are recommending an EPS of between $5.6 and $4.87 for the fiscal current year, implying an average EPS of $5.27. EPS for the following year is $21.49, with 17.0 analysts recommending between $25.45 and $16.64.
Revenue Estimates
16 analysts predict $1.11B in revenue for the current quarter. It ranges from a high estimate of $1.13B to a low estimate of $1.07B. As of the current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.05BFor the next quarter, 16 analysts are estimating revenue of $1.16B. There is a high estimate of $1.22B for the next quarter, whereas the lowest estimate is $1.13B.
A total of 17 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.3B, while the lowest revenue estimate was $4.16B, resulting in an average revenue estimate of $4.21B. In the same quarter a year ago, actual revenue was $4.07BBased on 18 analysts’ estimates, the company’s revenue will be $4.46B in the next fiscal year. The high estimate is $4.78B and the low estimate is $4.17B.
